for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

rovi.f

Latest Trade

20.40EUR

Change

-0.20(-0.97%)
0

Today's Range

20.40

 - 

20.40

52 Week Range

15.75

 - 

23.00

As of on the Frankfurt Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
20.60
Open
20.40
Volume
0
3M AVG Volume
0.21
Today's High
20.40
Today's Low
20.40
52 Week High
23.00
52 Week Low
15.75
Shares Out (MIL)
55.38
Market Cap (MIL)
1,429.76
Forward P/E
52.52
Dividend (Yield %)
0.31

Latest Developments

More

Rovi 9-Month Net Profit Up At 30.7 Mln Euros YoY

Rovi H1 Net Profit Up At 16.2 Mln Euros YoY

Rovi Q1 Ebitda Up At 11.9 Mln Euros YoY

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About

Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The Company owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

Industry

Biotechnology & Drugs

Contact Info

Calle Jose Isbert,2.

+34.913.756230

https://www.rovi.es/

Executive Leadership

Juan Lopez-Belmonte Lopez

Chairman of the Board

Juan Lopez-Belmonte Encina

Chief Executive Officer, Executive Director

Javier Lopez-Belmonte Encina

Second Vice Chairman of the Board, Chief Financial Officer, Executive Director

Ivan Jorge Lopez-Belmonte Encina

First Vice Chairman of the Board, Executive Director of Corporate Development

Pablo Dominguez Jorge

Chief Economic and Administrative Officer

Key Stats

2.70 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.3K

2017

0.3K

2018

0.3K

2019(E)

0.4K
EPS (EUR)

2016

0.455

2017

0.350

2018

0.350

2019(E)

0.485
Price To Earnings (TTM)
43.55
Price To Sales (TTM)
4.03
Price To Book (MRQ)
4.50
Price To Cash Flow (TTM)
30.86
Total Debt To Equity (MRQ)
14.13
LT Debt To Equity (MRQ)
10.66
Return on Investment (TTM)
11.21
Return on Equity (TTM)
8.57

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up